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Impact of Phenol-Enriched Virgin Olive Oils on the
Postprandial Levels of Circulating microRNAs Related to
Cardiovascular Disease
Lidia Daimiel,* Víctor Micó, Rosa M Valls, Anna Pedret, María José Motilva, Laura Rubió,
Montse Fitó, Marta Farrás, María Isabel Covas, Rosa Solá, and José M. Ordovás
Scope: We investigate the postprandial modulation of cardiovascular-related
microRNAs elicited by extra virgin olive oil (EVOOs) containing different
levels of their own polyphenols.
Methods and results: It is randomized, postprandial, parallel, double-blind
study. Twelve healthy participants consumed 30 mL of EVOO containing low
(L-EVOO; 250 mg total phenols kg−1 of oil), medium (M-EVOO; 500 mg total
phenols kg−1 of oil), and high (H-EVOO; 750 mg total phenols kg−1 of oil)
enriched EVOOs. Postprandial plasma microRNAs levels are analyzed by
real-time quantitative PCR. The results show that L-EVOO intake is associated
with decreased let-7e-5p and miR-328a-3p levels and increased miR-17-5p and
miR-20a-5p, concentrations. M-EVOO decreases plasma let-7e-5p and
increases miR-17-5p, miR-20a-5p, and miR-192-5p levels. Finally, H-EVOO
decreases let-7e-5p, miR-10a-5p, miR-21-5p, and miR-26b-5p levels.
Conclusion: During the postprandial state, the levels of let-7e-5p decrease
with EVOO regardless of polyphenol content suggesting a general response
to the fatty acid composition of EVOO or/and the presence of at least 250 mg
polyphenol kg−1 olive oil. Moreover, the miR-17-92 cluster increases by low
and medium polyphenol content suggesting a role in fatty acid metabolism
and nutrient sensing. Thus, postprandial modulation of circulating
microRNAs levels could be a potential mechanism for the cardiovascular
benefits associated with EVOO intake.
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1. Introduction
Extra virgin olive oil (EVOO) is a corner-
stone of the Mediterranean diet (MD),
and its health properties were initially
attributed to its fatty acid composition
and later to its unique mix of minor
components (i.e., polyphenols).[1,2] Ob-
servational studies, such as The Three-
City Study, found an association between
olive oil consumption and a lower inci-
dence of stroke in older subjects.[3] This
was also the outcome of the random-
ized controlled trial Prevención con Dieta
Mediterránea (PREDIMED) Study that
showed a lower incidence of cardiovascu-
lar disease (CVD) in the group following
the traditional MD supplemented with
EVOO in comparison with the low-fat
diet control group.[4]
Oleic acid has been associated with an
increase in HDL-cholesterol levels and a
decrease in LDL oxidation.[5,6] Addition-
ally, some EVOO polyphenols have been
suggested to function as chemoprotec-
tive agents.[7] Hydroxytyrosol, the most
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representative polyphenol of EVOO, is a phenolic alcohol that
functions as a scavenger of free reactive oxygen species and
has antioxidant properties.[8] Moreover, EVOO also has anti-
inflammatory, antiplatelet, anti-atherogenic,[9] anti-tumor,[10] and
neuroprotective properties.[11]
Despite numerous reports describing the beneficial effect of
EVOO consumption, knowledge about the molecular mecha-
nisms explaining such properties is still sparse. Most researchers
have focused on how EVOO modulates gene expression in cell
lines and murine models[12] with less information being avail-
able in humans. One of such studies is the Virgin Olive Oil
and HDL Functionality (VOHF) Study.[13] This is a randomized,
double-blind, crossover, controlled trial that compared the ef-
fect of three different levels of endogenous polyphenols using
the same EVOO on HDL-cholesterol changes in hypercholes-
terolemic patients.[6] Following a nutrigenomics approach, other
interventional studies with olive oil have reported changes in the
expression of genes related to inflammation, oxidative stress,
lipid metabolism, cellular apoptosis, and DNA damage.[14,15]
However, the influence of three different olive oil endogenous
polyphenol concentrations on microRNAs is unknown. MicroR-
NAs are non-coding RNA sequences of 22 to 24 nucleotides
whose primary function is to “fine-tune” gene expression and
are critical regulators of many cellular processes. MicroRNAs
have been associated with many diseases such as cancer, CVD,
diabetes, and neurological disorders.[16,17] Interestingly, microR-
NAs can be found in circulation,[18] and they could serve as
disease or nutritional status biomarkers.[19] Several studies in
cell and animal models have shown that dietary compounds can
modulate the levels of microRNAs.[20,21] Specifically in a murine
model, it was found that enriched polyphenol EVOO intake
modified the expression of brain microRNAs related to the age-
related decline of motor coordination and contextual memory.[22]
However, although a few studies have investigated the modula-
tion of microRNAs by dietary factors in humans,[23,24] no studies
have reported on the postprandial modulation of circulating
microRNAs by EVOO intake.
The objective of this research was to examine postprandial
changes in circulating microRNAs levels after acute intake of
three phenol enriched EVOOs containing different concen-
trations of polyphenols from olive oil in healthy volunteers
and to identify metabolic pathways targeted by modified
microRNAs.
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2. Results
2.1. Postprandial Modification of Plasma microRNA Levels with
Functional Olive Oils
Four plasma microRNAs were significantly modulated by L-
EVOO (Figure 1A). Let-7e-5p showed a bimodal distribution with
two peaks of repression at 1 Fold change abbreviation to be added
(FC = −2.147 ± 0.473, p = 0.007) and 4 (FC = −1.879 ± 0.637,
p = non significant) h. miR-17-5p and miR-20a-5p were upregu-
lated after consumption of L-EVOO along the whole postprandial
curve with a maximum at 4 (FC = 0.724 ± 0.247, p = 0.031) h
and 1 (FC = 0.615 ± 0.162, p = 0.006) and 2 (FC = 0.724 ± 0.205,
p = 0.007) h, respectively. On the other hand, miR-328a-3p
was downregulated after L-EVOO intake with a minimum of
expression at 1h (FC = −1.179 ± 0.172, p = 0.006).
Three microRNAs were modulated by M-EVOO (Figure 2A).
Let-7e-5p showed a similar pattern thanwith L-EVOO (p= 0.025),
although these results were not significant after Bonferroni cor-
rection in intra-subject comparisons. The miR-17-5p linear trend
was not significantly modified, although we observed a signifi-
cant overexpression at 6 h when comparing with 2 h (FC = −0.2,
p = 0.05). Finally, miR-192-5p was significantly upregulated
by the M-EVOO. miR-328a-3p and miR-20a-5p showed the
same trend observed with L-EVOO, without reaching statistical
significance (Figure S1, Supporting Information).
Four microRNAs were significantly modified by H-EVOO
(Figure 3); all of them were downregulated after 2 h of the
H-EVOO ingestion. We also observed a bimodal distribution of
postprandial circulating let-7e-5p levels with a minimum at 2 h
(FC = −1.181, p = 0.02).
2.2. In Silico Functional Analyses
We selected the genes that are predicted and validated targets of
at least 2/4 microRNAs in L-EVOO, 2/3 mRNAs in M-EVOO,
and 2/4 mRNAs in H-EVOO.
Functional analyses showed that 1361 genes were targets of
microRNAs modulated by L-EVOO, 1076 of them were targets
of miR-17-5p and miR-20a-5p, which belong to the same cluster
(Figure 1B). Targeted genes were mainly linked to different
types of cancer and related processes (Table S3, Supporting
Information). Among the enriched pathways, we also observed
mTOR, AMPK, FOXO, and insulin signaling pathways as signif-
icantly modulated by miR-17-5p and miR-20a-5p and fatty acid
biosynthesis as significantly modulated by let-7e-5p (Figure 1C).
Fourteen genes were predicted or validated targets of all those
miRNAs (Figure 1B and Table S4, Supporting Information),
Interestingly, 30 genes were predicted or validated targets of
let-7e-5p and miR-328a-3p, both downregulated at 1 h (Figure 1B
and Table S4, Supporting Information). Three hundred eighty-
one genes were validated or predicted targets of microRNAs
modulated by M-EVOO (Figure 2B). These microRNAs were
involved in different types of cancer and related processes
(Figure 2C and Table S3, Supporting Information). Interestingly,
they were also involved in fatty acid biosynthesis (let-7e-5p),
FOXO and PI3K/AKT signaling (let-7e-5p and miR-17-5p),
AMPK and mTOR signaling (miR-17-5p), and steroid and folate
biosynthesis (miR-192-5p) (Figure 2C). Twenty-five of these
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Figure 1. microRNAs modulated by L-EVOO. A) Box plots showing Log2 transformed relative quantification levels of indicated microRNAs along the
postprandial phase (n = 8). p-value refers to the intra-subject’s comparison of the paired-repeated measures ANOVA with Bonferroni correction. *p <
0.05. B) Venn diagram showing common targets of the modulated microRNAs. C) Heatmap plot of significant KEGG pathways (Log10).
genes were predicted targets for all three microRNAs (Figure 2B
and Table S5, Supporting Information).
Four hundred fifty-four genes were validated or predicted
targets of microRNAs modulated by H-EVOO (Figure 3B).
These microRNAs were involved in different types of cancer and
related pathways. However, they were also involved in fatty acid
metabolism: fatty acid biosynthesis (let-7e-5p and miR-10a-5p),
synthesis of unsaturated fatty acids (miR-21-5p andmiR-26b-5p),
and fatty acid elongation (miR-21-5p) (Figure 3C and Table S3,
Supporting Information). YOD1 gene was the only predicted
target of all four microRNAs. YOD1 is a protein deubiquitinase
involved in many cellular processes, including cell cycle, signal
transduction, inflammation, and synthesis of unsaturated fatty
acids.[25]
2.3. microRNA Levels According to the Type of Functional Oil
Next, we performed interaction analyses to compare microRNA
levels across the functional olive oils under investigation
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Figure 2. microRNAs modulated by M-EVOO. A) Box plots showing Log2 transformed relative quantification levels of indicated microRNAs along the
postprandial phase (n = 11). p-value refers to the intra-subject’s comparison of the paired-repeated measures ANOVA with Bonferroni correction.
*p < 0.05. B) Venn diagram showing common targets of the modulated microRNAs. C) Heatmap plot of significant KEGG pathways (Log10).
(Figure 4A). Interestingly, let-7e-5p showed the same bimodal
response to all functional oils, although the trend was delayed
for 1 h with the H-EVOO. Interaction analyses for miR-126-
3p, miR-24-3p, and miR-328a-3p levels were not significant.
However, it is worth mentioning that circulating levels of these
microRNAs with L-EVOO and M-EVOO showed a more similar
trend between them than with H-EVOO. The interaction be-
tween circulating miR-26b-5p levels and the type of functional
oil was significant (p = 0.043), with a similar pattern found with
low and medium EVOO than with H-EVOO. More specifically,
miR-26b-5p circulating levels barely changed along the post-
prandial phase with L-EVOO and M-EVOO, while they were
significantly downregulated after 2 h of the ingestion ofH-EVOO.
H-EVOO and M-EVOO modified circulating levels of miR-192-
5p oppositely. While M-EVOO leads to a postprandial increase,
H-EVOO resulted in a postprandial decrease of circulating miR-
192-5p (FC (2 h) ≈2.0; p = 0.041). Finally, miR-20a-5p plasma lev-
els were similarly modified by L-EVOO and M-EVOO. However,
the early increase observed was more pronounced with L-EVOO,
while the late decrease was more pronounced with M-EVOO.
After 6 h, levels had come back to basal levels in the two cases.
We then performed an in silico analysis to define which genes
are frequent targets of microRNAs modulated by the three
functional oils (Figure 4B). Forty-four genes were predicted and
validated targets of microRNAs modified by all three oils. Those
genes were involved in different types of cancers, as well as in
AMPK, MAPK, and FOXO signaling and the circadian system
(Figure S2 and Table S6, Supporting Information).
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Figure 3. microRNAs modulated by H-EVOO. A) Box plots showing Log2 transformed relative quantification levels of indicated microRNAs along the
postprandial phase (n = 10). p-value refers to the intra-subject’s comparison of the paired-repeated measures ANOVA with Bonferroni correction.
*p < 0.05. B) Venn diagram showing common targets of the modulated microRNAs. C) Heatmap plot of significant KEGG pathways (Log10).
2.4. Correlation between Circulating Levels of Modified
microRNAs and Plasma Lipid and Glucose Levels
We aimed to define if changes in circulating levels of the differ-
entially modulated microRNAs were correlated with changes in
circulating levels of biochemistry parameters used as biomarkers
of metabolic disorders like lipid and glucose levels. We found
that the decrease in miR-328a-3p after 4 h of L-EVOO ingestion
correlated with a decrease inHDL plasma levels at the same time-
point (R = 0.68, p = 0.033) (Figure S3C, Supporting Information
and Figure 5) and the increase inmiR-20a-5p after 6 h of L-EVOO
ingestion correlated with a decrease in total cholesterol
(R = −0.68, p = 0.033) (Figure S3D, Supporting Information and
Figure 5).
The increase in miR-17-5p levels correlated with a decrease in
total cholesterol 2 h after the ingestion of M-EVOO (R = −0.5,
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Figure 4. Differentially modulated microRNAs according to the type of functional oil. A) Interaction plots showing Log2 transformed relative quantifi-
cation levels of indicated microRNAs along the postprandial phase in the three functional olive oils. p-value refers to analyses of the paired-repeated
measures ANOVA with oil type as interaction parameter and Bonferroni correction. *p < 0.05, **p < 0.001. B) Venn diagram showing common targets
of the modulated microRNAs in the three functional oils.
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Figure 5. Correlation plots of microRNAsmodulated by L-EVOO. Correlation with lipid and glucose metabolic markers and endothelial function markers
was calculated by Tau Kendall test.
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p = 0.034) (Figure S4B, Supporting Information and Figure 6A)
and the increase in miR-192-5p levels correlated with increased
levels of triglycerides (TG) after 6 h of M-EVOO ingestion (R =
0.59, p = 0.01) (Figure S4D, Supporting Information and Fig-
ure 6C). Finally, the decrease in miR-26b-5p levels correlated
with a decrease in glucose level after 2 h of H-EVOO ingestion
(R = 0.6, p = 0.016) (Figure S5B, Supporting Information and
Figure 7A).
2.5. Correlation between Circulating Levels of Modified
microRNAs and Markers of Endothelial Function
Finally, we investigated if changes in microRNA levels correlated
with changes in circulating levels of two markers of endothelial
function and atherosclerosis: endothelin and oxidized-LDL. We
found interesting correlations between changes in microRNA
levels after 4 h of L-EVOO ingestion and changes in total oxLDL
and nitrites levels (Figure S3C, Supporting Information). We
found that a higher decrease of let-7e-5p levels correlated with
a lower decrease in nitrates levels at 4 h (R = −0.81, p = 0.011)
(Figure S3C, Supporting Information and Figure 5). We observed
that the increase in circulating levels of miR-17-5p mediated
by L-EVOO correlated with an increase in oxLDL (R = 0.81,
p = 0.011) and in oxLDL/LDL ratio (R = 0.71, p = 0.03) after
4 h (Figure S3C, Supporting Information and Figure 5). The
increase in miR-192-5p levels correlated with an increase in en-
dothelin levels at 4 h of ingestion of M-EVOO (R = 0.6, p = 0.01)
(Figure S4C, Supporting Information and Figure 6B). Finally, the
decreased in miR-21-5p levels observed 2 h after the ingestion
of H-EVOO correlated with increase in both, LDLox (R = −0.56,
p = 0.029) and the ratio LDLox/LDL (R = −0.51, p = 0.047) at
the same time-point (Figure S5B, Supporting Information and
Figure 7A). On the other hand, the decrease in miR-10a-5p levels
after 4 h of H-EVOO ingestion correlated with higher endothelin
levels at the same time-point (R = −0.6, p = 0.017) (Figure S5C,
Supporting Information and Figure 7B).
3. Discussion
Our study shows the postprandial modification of circulating
microRNAs after intake of three different functional olive oils
enriched with their own polyphenols. Some recent reports have
shown the change of postprandial levels of circulating microR-
NAs in response to fat challenges or mixed meal challenges
in humans.[26,27] Although these reports only compare basal
fasting levels to one postprandial timepoint. The study reported
by Qintanilha et al. analyzed the effect of a high-fat breakfast on
circulating levels of microRNAs after 1, 3, and 5 h (4 timepoints,
up to 5 h post-ingestion), although they did not conduct time-
dependent analyses.[28] We studied circulating microRNAs levels
at basal time and after 1, 2, 4, and 6 h (5 timepoints, up to 6 h post-
ingestion) of ingestion of 30 mL of three functional extra virgin
olive oils with different polyphenolic content. Thus, to the best of
our knowledge, this is the first study analyzing the postprandial
behavior of human plasma microRNAs with this level of detail.
Figure 6. Correlation plots of microRNAs modulated by M-EVOO. Corre-
lation with lipid and glucose metabolic markers and endothelial function
markers was calculated by Tau Kendall test. A) Correlation between FC in
miR-17-5p and in total cholesterol after 2 h. B) Correlation between FC in
miR-192-5p and endothelin after 4 h. C) Correlation between miR-192-5p
and TG after 4 h.
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Figure 7. Correlation plots of microRNAsmodulated by H-EVOO. Correlation with lipid and glucosemetabolic markers and endothelial functionmarkers
was calculated by Tau Kendall test. A) Correlation between FC in miR-21-5p and in oxLDL and oxLDL/LDL ration and between FC in miR-26b-5p and
glucose after 2 h. B) Correlation between FC in miR-10a-5p and endothelin after 4 h.
Some previous studies have reported postprandial changes in
microRNA levels in fish tissues (liver and muscle), suggesting
that early changes in microRNA levels as a response to diet are
biologically plausible.[29,30] López et al. studied the postprandial
response of microRNAs to a high-saturated fat meal in periph-
eral blood mononuclear cells of nine healthy young men[31]
and showed nine regulated microRNAs after 2 h of the fat load.
Rodríguez-Ayala et al. found that the circulating levels of some
microRNAs related to adipose tissue function were changed after
3 h of a balanced mixed meal.[27] Mantilla-Escalante et al. studied
in detail the postprandrial response of circulating microRNAs
to a high-fat diet consisted of the administration (oral gavage) of
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250 µL olive oil enriched with 40 mg of cholesterol to wild-type
and DICER knock out mice.[26] None of their significantly modu-
latedmicroRNAs were in our panel. Although we cannot rule out
the fact that these microRNAs could also be modulated in our
volunteers, we must bear in mind that postprandial microRNAs
modulated in mice can significantly differ from those modulated
in humans. Besides, the fat challenge was based on olive oil
(authors do not specify the type of olive oil) and cholesterol.
Finally, this report measures three of the modified microRNAs
in ten healthy subjects at baseline and after 3 h of a fat load not
containing olive oil.[26] Differences in the experimental design
and the microRNAs analyzed between this report and ours make
difficult to comparatively discuss the results. Quintanilha et al.
also analyzed circulating plasmamicroRNA levels along 3 h after
the ingestion of a high-saturated fat breakfast.[28] They found up
to 33 differently expressed microRNAs, comparing each time-
point to basal level. Among them, miR-145-5p andmiR-200 were
modulated at all timepoints. They also found an increase in miR-
143-3p, miR-375-3p, miR-33b-5p, and a decrease in miR-92b-3p.
We did not find changes in these microRNAs in our postprandial
challenge. The discordant results could be due to the difference
between Quintanilha et al. challenge, rich in saturated fats and
ours, based on extra-extra virgin olive oil enriched in polyphenols.
This suggest that circulating levels of microRNAs we identified
are modulated specifically by unsaturated fats and polyphenols.
Our design and analysis method allow us to define more
precise postprandial kinetics of microRNAs. In this regard, dif-
ferent behaviors have been found with our different functional
oils, such as bimodal (let-7e-5p), increased (miR-17-5p, miR-20a-
5p, and miR-192-5p), or decreased (miR-328a-3p, miR-10a-5p,
miR-21-5p, and miR-26b-5p) responses.
One of our most striking finding is the consistent increase
of plasma miR-17-5p and miR-20a-5p, two members of the
miR-17-92 cluster (also known as oncomiR-1), by L-EVOO and
M-EVOO. Specifically, both microRNAs presented an increasing
postprandial curve with peaks at 2 or 4 h. These results point
toward a key role of this cluster in the postprandial response
to these functional olive oils. These results are in agreement
with those from Lopez et al.[31] who found that miR-18a-3p and
miR-19b-1-5p (two other members of the miR17-92 cluster) were
upregulated in peripheral mononuclear cells 2 h after the fat
load, and with those reported by Ortega et al.,[23] who found
miR-18a and miR-19, other members of the cluster, upregulated
in obese individuals after 8 weeks of an isocaloric diet enriched
in 𝜔-3 and 𝜔-6 polyunsaturated fatty acids. The increased expres-
sion of the miR-17-92 cluster has been associated with different
types of cancer, where it plays a key role in the metabolic re-
programming of tumour cells.[32] The overexpression of the
miR-17-92 cluster has been found to enhance glycolysis and ox-
idative phosphorylation in tumor cells, with different members
of the cluster having different effects.[32] In this regard, the lack
of miR-92a has been found to increase glycolytic and oxidative
metabolism, whereas the lack of miR-17 and miR-20a is most
effective in reducing glycolytic and oxidative metabolism.[32]
Lack of miR-17 and miR-20a has also been found to increase
AMPK and decrease mTOR signaling pathways.[32] Our in silico
analysis showed that these nutrient-sensing pathways were
significantly enriched among the processes regulated by miR-17
and miR-20a. Apart from its role in cancer, the cluster miR-17-92
also plays important roles in lipid and glucose metabolism,[33]
endothelial cell function,[34] and macrophage differentiation[35]
all of them related to CVD. Interestingly, circulating levels of
miR-17 and miR-20a have been found upregulated. In contrast,
circulating levels of the other members of the miR-17-92 cluster
have been found downregulated in patients with coronary artery
disease and miR-17 levels have been positively associated with
hyperlipidaemia and total cholesterol levels.[36] We found inter-
esting correlations between changes in circulating miR-17-5p
levels and changes in CVD biomarkers such as oxLDL and
total cholesterol after the ingestion of L-EVOO and M-EVOO,
supporting a role of this cluster in CVD, and suggesting that
the impact of our enriched EVOO on CVD biomarkers could be
mediated by this microRNA. Plasma let-7e-5p was reduced by
all three functional oils, suggesting that it is a primary target of
dietary modification either by monounsaturated fatty acids or oil
polyphenols. Let-7e is downregulated after intensive exercise[37]
and upregulated in coronary artery disease patients.[36] Plasma
let-7e has been found to increase in children with metabolic
syndrome and correlated with waist circumference, insulin
resistance, and with the accumulation of metabolic syndrome
traits.[38] Moreover, in children with metabolic syndrome, a
negative association of plasma let-7e and HDL was found.[38] We
also found a significant negative correlation between let-7e with
total cholesterol, LDL-c, and HDL-c at 1 h after the ingestion of
L-EVOO. Interestingly, serum let-7e levels are also increased in
ischemic stroke patients[39,40] and varied in different stages, be-
ing higher in the acute phase and lower in the recovery phase.[39]
As Let-7e is a key regulator of endothelial function and immune
activity and promotes inflammation,[41] low levels of plasma
let-7e can indicate a good health condition produced by EVOO,
by olive oil or/and at least a 250 mg polyphenol kg−1 olive oil.
Another interesting finding refers to the different postpran-
dial microRNA profile associated with H-EVOO ingestion in
comparison with L-EVOO (250 mg polyphenol kg−1 EVOO) and
M-EVOO (500 mg polyphenol kg−1 EVOO) that showed a more
similar pattern. It is worth mentioning that the three functional
oils share the same matrix and the only difference among them
is their polyphenolic content. It is possible that a higher polyphe-
nol enrichment has different effects on molecular pathways and
a different biological impact. In this regard, it has been shown
that an excess of polyphenols could produce pro-inflammatory
effects.[42] Moreover, preliminary studies to select the dosage that
provided the highest beneficial effects on cardiovascular and en-
dothelial parameters showed that EVOO enriched with 500 mg
kg−1 provided additional benefits in comparison with those en-
riched with 250 and 750 mg kg−1.[43] This study also showed that
plasma phenolic concentration was not linearly correlated with
dosage after 500 mg kg−1.[43] Phenolic concentration in virgin
olive oil is very variable (0.02 to 600 mg kg−1) and it depends
on different factors like cultivation area, irrigation techniques,
the age of the olive tree, maturation of the olive fruit at harvest,
the oil extraction process, storage conditions, and cooking
techniques.[44] According to the Commission Regulation (EU)
432/2012, the health claim regarding the protection of lipid from
oxidative stress attributed to olive oil “may be used only for olive
oil which contains at least 5 mg of hydroxytyrosol and its derivatives
(e.g., oleuropein complex and tyrosol) per 20 g of olive oil.” Thus,
250 mg of polyphenol kg−1 is considered healthy extra virgin oil.
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Our results suggest that an enrichment with up to 500 mg kg−1
of polyphenols may improve the benefits associated with olive oil
consumption. Our results with H-EVOO suggest a microRNA
profile more associated with hypertension. These results suggest
that the different effects of H-EVOO on microRNA levels could
be, in part, due to a detrimental effect of an excess of polyphenols
and thus, high concentration of polyphenols should be carefully
considered.
This study has some limitations. First, the small sample size
calls for validation in a larger clinical trial. Second, although cir-
culating plasmamicroRNAs have a high potential as biomarkers,
we cannot assert the impact of changes in circulating microRNA
levels on target cells. We cannot discern the tissue of origin nor
the target tissue of the microRNAs differentially modulated.
In this regard, further studies in animal models where the
postprandial expression of these microRNAs in different tissues
were assessed are needed. We should also bear in mind that this
is an acute postprandial study and some changes produced by
EVOO intake could need a more extended exposure. Moreover,
participants drunk 30 mL of EVOO that is a dose which is not
usually consumed in only one ingestion. It would be necessary
to carry out another intervention study with doses of EVOO
ingested regularly. Furthermore, further studies specifically de-
signed to analyze the effect of each specific polyphenol in every
concentration on the expression of the modulated microRNA are
needed to discern which component of our functional EVOOs is
affecting each microRNA concentration and regulation. Also, we
analyzed a selected panel of microRNAs. Therefore, we cannot
rule out the possibility that these functional oils modulate
circulating levels of other microRNAs associated with other
conditions. Finally, some technical limitations linked to the
detection and normalization of microRNAs in plasma could
interfere with the results by reducing sensitivity.
However, the microRNA results offer promising evidence
that paves the way for future studies addressing the biological
impact of microRNAs modification by olive oil and polyphenols
in humans. Notably, this study points to the decrease let-7e-
5p with low, medium, and high olive oil polyphenol content
consumption and the decrease miR-17-92 cluster after low and
medium polyphenol content as a potential mechanism of action
and biomarkers of the effect polyphenol content of extra virgin
olive oil postprandial intake.
4. Experimental Section
Study Design: The VOHF study was carried out in the Hospital
Universitari Sant Joan de Reus (Spain). The study design and charac-
teristics of the volunteers have been described in detail elsewhere.[43]
The study was a postprandial, randomized, controlled, crossover trial
with twelve healthy volunteers (50% women, 22–60 years) consisting
of the intake of 30 mL of the functional EVOOs after 12 h of fasting.
Three polyphenols-enriched EVOOs differing in phenolic content were
assessed: Low-EVOO (L-EVOO, 250 mg total phenols kg−1 of oil),
Medium-EVOO (M-EVOO, 500 mg total phenols kg−1 of oil), and High-
EVOO (H-EVOO, 750 mg total phenols kg−1 of oil). Composition of
the three functional oils is detailed in Table S1, Supporting Information.
Blood samples were collected at 1, 2, 4, and 6 h after the ingestion. The
intervention was carried out according to the guidelines laid down in the
Declaration of Helsinki, and all procedures involving human subjects
were approved by the local IRB (Clinical Research Ethical Committee,
University Hospital Sant Joan, Reus, Spain (Ref 09-02-26/2proj2) and was
registered at ClinicalTrials.gov (Identifier: NCT01347515). All participants
provided informed written consent.
Dosage Information: The volunteers ingested 30 mL of the functional
EVOOs after 12 h of fasting. The three polyphenols-enriched EVOOs
deferred in phenolic content: L-EVOO (250 mg total phenols kg−1 of
oil), M-EVOO (500 mg total phenols kg−1 of oil), and H-EVOO (750 mg
total phenols kg−1 of oil). The oil matrix of the three oils was the same.
The preparation of the functional oils has been previously detailed.[43]
They were prepared by adding an extract obtained from freeze-dried olive
cake rich in the main olive oil phenolic compounds to an extra virgin
olive oil matrix with low phenolic content (80 mg total phenols kg−1 of
oil).[43] This dose of these functional oils ingested in a single dose after
fasting did not result in adverse events and previous results suggest that
the M-EVOO could provide additional cardiovascular benefits.[43] In the
Mediterranean population, the mean intake of EVOO is 40 g per day (≈3
tablespoons per day).[4] This study reduced the intake to 30 mL because
this dose was ingested in an single intake after 12 h fasting.
Analyses of microRNAs Circulating Levels: Plasma was obtained from
fresh blood by centrifugation. MicroRNA-enriched total RNA from 200 µL
of plasma was isolated with miRCURY RNA Isolation Kit – Biofluids
(Exiqon, A/S, Vedbaek, Denmark) using manufacturer’s instructions and
were diluted in 50 µL of RNase-free water.
A panel of 53 microRNAs related to CVD was selected by using pre-
diction algorithms such as miRWalk[45] and miRbase[46] and a literature
search (Table S2, Supporting Information).
MicroRNA levels were analysed by Real-Time quantitative PCR (RT-
qPCR). Isolated microRNAs were retro transcribed with the TaqMan Mi-
croRNAReverse Transcription Kit (Thermo Fisher Scientific,Waltham,MA,
USA). Before retro transcription, 5 fmol of single-strand cel-miR-54 was
added to control for retro transcription variability. 5 µL of RNA were used
as a template. Resulting cDNAwas pre-amplifiedwith the TaqMan PreAmp
Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) and amplified
by RT-qPCR with TaqMan OpenArray PCR Master Mix (Thermo Fisher
Scientific, Waltham, MA, USA) in a TaqMan custom OpenArray loaded
using an OpenArray AccuFill System (Thermo Fisher Scientific, Waltham,
MA, USA). The RT-qPCR was run in a QuantStudio 12K Flex Real-Time
PCR System with OpenArray Block (Thermo Fisher Scientific, Waltham,
MA, USA). The fold-change (FC) in circulatingmicroRNAs levels wasmea-
sured as relative quantification using the 2−ΔΔCt method comparing each
time-point to the basal point and was Log2 transformed. The best two
endogenous reference microRNAs were identified with the NormFinder
algorithm.[47] The quadratic average of the two endogenous controls plus
the exogenous cel-miR-54 control was used for normalization.
In Silico Functional Analyses: MicroRNAs significantly modified in,
at least, one time-point in each treatment were selected for further
functional analyses. Enrichment analysis was carried out with DIANA
miRPath v0.3[48] and targets of these microRNAs were identified using
the miRWalk tool[45] and analyzed for functionality with Babelomics 5 and
Software String.[49,50]
Statistical Analyses: Changes in circulating microRNAs levels along
the postprandial curve were analyzed by repeated-measurements ANOVA
with Bonferroni correction. Missing values were imputed using a multi-
variate linear regression model. Imputed values accounted for less than
10% of all values. The interaction with the type of oil was included in
the analysis. Data are shown as fold change (FC) ± standard error of the
mean. A two-tailed p-value of 0.05 was considered significant. Statistical
analyses were made with SPSS v24.
Statistical significance for enriched GO biological processes and KEGG
pathways were analyzed with Babelomics 5, Diana miRPath v0.3, and
Software String algorithms applying a False Discovery Rate adjustment.
Overrepresented KEGG pathways are shown in heat maps with the color
representing the log10 of the p-value.
Venn diagrams were built with the Bioinformatics and Evolutionary
Genomics application using default settings (http://bioinformatics.psb.
ugent.be/webtools/Venn/).
Changes in concentration of microRNAs with respect to basal time
were correlated with changes in biochemical parameters with Tau Kendall
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test and heatmap correlation plots were created using Corrplot package
in R i386 3.5.2 using RStudio.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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